Week-by-week dose escalation protocol based on SURMOUNT trial data
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that requires careful dose titration to minimize gastrointestinal side effects. This guide covers the standard titration schedule used in clinical trials, practical injection protocols, and strategies for managing the dose escalation process.
The titration schedule used in SURMOUNT trials: Weeks 1–4: 2.5 mg/week. Weeks 5–8: 5 mg/week. Weeks 9–12: 7.5 mg/week (optional maintenance). Weeks 13–16: 10 mg/week. Weeks 17–20: 12.5 mg/week. Week 21+: 15 mg/week (maximum maintenance). Many researchers use a slower schedule — 4–8 weeks at each dose level — to minimize GI side effects, especially in the early titration phase.
Tirzepatide is administered via subcutaneous injection once weekly. Injection sites: abdomen, thigh, or upper arm. Rotate injection sites each week. Inject on the same day each week. Reconstituted tirzepatide should be stored at 2–8°C and used within 28 days of reconstitution.
SURMOUNT-1 results by maintenance dose: 5 mg/week: 15.0% mean body weight reduction. 10 mg/week: 19.5% mean body weight reduction. 15 mg/week: 20.9% mean body weight reduction. Higher doses produce greater weight loss but also higher rates of GI side effects. Most researchers target 10–15 mg/week as the maintenance range.
The most common side effects during titration are nausea, vomiting, and diarrhea, which typically peak in the first 1–2 weeks after each dose increase and then subside. Strategies: eat smaller meals, avoid high-fat foods, stay well hydrated, consider a slower titration schedule if side effects are severe. If side effects are intolerable at a given dose, some protocols hold at the previous dose for an additional 4 weeks before re-attempting escalation.
Tirzepatide's maximum dose (15 mg/week) produces greater weight loss than semaglutide's maximum dose (2.4 mg/week) — 20.9% vs 14.9% in respective trials. However, tirzepatide's titration schedule is longer (20+ weeks to reach maximum dose vs 16–17 weeks for semaglutide) and GI side effects may be more pronounced at higher doses. See the full comparison for a detailed breakdown.
The standard titration to the maximum dose of 15 mg/week takes approximately 20 weeks. Many researchers use a slower schedule (4–8 weeks per step), which can extend titration to 30–40 weeks for better tolerability.
Skipping doses is not recommended as it can disrupt plasma level stability and increase side effects when dosing resumes. If a dose is missed by less than 4 days, take it as soon as possible. If more than 4 days have passed, skip the missed dose and resume the regular schedule.
The maximum approved dose for tirzepatide is 15 mg/week. Clinical trials have not evaluated doses above 15 mg/week. Most weight loss benefit is achieved between 10–15 mg/week.
No — tirzepatide's standard titration to maximum dose takes approximately 20 weeks, compared to 16–17 weeks for semaglutide. However, tirzepatide achieves greater weight loss at its maximum dose.
Research Use Only
All content is for educational and research purposes. Not medical advice. Consult a qualified healthcare professional before considering any peptide protocol.
Parent Guide
Tirzepatide Dosage GuideResearch Grade
Shop Purgo Labs
Use Code HEALTH for 15% OffMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.